Bronchiectasis and increased mortality in patients with corticosteroid-dependent severe asthma: a nationwide population study

被引:25
|
作者
Choi, Hayoung [2 ,3 ]
Lee, Hyun [1 ]
Ryu, Jiin [4 ]
Chung, Sung Jun [1 ]
Park, Dong Won [1 ]
Sohn, Jang Won [1 ]
Yoon, Ho Joo [1 ]
Kim, Sang-Heon [1 ]
机构
[1] Hanyang Univ, Dept Internal Med, Coll Med, 222 Wangsimni Ro, Seoul 04763, South Korea
[2] Hallym Univ, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Kangnam Sacred Heart Hosp, Seoul, South Korea
[3] Hallym Univ, Lung Res Inst, Coll Med, Chunchon, South Korea
[4] Hanyang Univ, Med Res Collaborating Ctr, Biostat Consulting & Res Lab, Seoul, South Korea
关键词
asthma; bronchiectasis; corticosteroid; epidemiology; mortality; HEALTH-CARE;
D O I
10.1177/1753466620963030
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Long-term corticosteroid (CS) use is associated with increased mortality in patients with asthma, and comorbid bronchiectasis is also associated with frequent asthma exacerbation and increased healthcare use. However, there is limited information on whether bronchiectasis further increases mortality in patients with CS-dependent asthma. This study examined the impact of bronchiectasis on mortality in patients with CS-dependent asthma. Methods: A retrospective cohort of patients with CS-dependent asthma > 18 years old was established using records from the Korean National Health Insurance Service database from 2005 to 2015. Patients with CS-dependent asthma with and without bronchiectasis were matched by age, sex, type of insurance, and Charlson comorbidity index. We evaluated the hazard ratio (HR) for all-cause mortality in patients with bronchiectasis compared with those without bronchiectasis. Results: The study cohort included 754 patients with CS-dependent asthma with bronchiectasis and 3016 patients with CS-dependent asthma without bronchiectasis. Patients with CS-dependent asthma with bronchiectasis had a higher all-cause mortality than those without bronchiectasis (8429/100,000versus6962/100,000 person-years, p < 0.001). The adjusted HR for mortality in patients with CS-dependent asthma with bronchiectasis relative to those without bronchiectasis was 1.33 (95% confidence interval, 1.18-1.50), and the association was primarily significant for respiratory diseases (subdistribution HR = 1.65, 95% confidence interval, 1.42-1.92). Conclusions: Bronchiectasis further increases all-cause mortality in patients with CS-dependent asthma, a trend that was especially associated with respiratory diseases including chronic obstructive pulmonary disease. Strategies to improve treatment outcomes in patients with CS-dependent asthma with bronchiectasis are urgently needed to improve long-term survival. The reviews of this paper are available via the supplemental material section.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] miR-144-3p Is a Biomarker Related to Severe Corticosteroid-Dependent Asthma
    Rodrigo-Munoz, Jose M.
    Gil-Martinez, Marta
    Lorente-Sorolla, Clara
    Garcia-Latorre, Raquel
    Valverde-Monge, Marcela
    Quirce, Santiago
    Sastre, Joaquin
    del Pozo, Victoria
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] ASTHMA-RELATED HEALTH CARE UTILIZATION IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT ASTHMA
    Buck, P. O.
    Small, Buatti M.
    Hankin, C. S.
    Bronstone, A.
    Wang, Z.
    Gopalan, G.
    Lepore, M.
    VALUE IN HEALTH, 2013, 16 (03) : A233 - A233
  • [33] DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA
    Sher, Lawrence
    Wolfe, Robert
    Quirce, Santiago
    Cohn, Lauren
    Passalacqua, Giovanni
    Paggiaro, Pierluigi
    Taille, Camille
    Daizadeh, Nadia
    Ortiz, Benjamin
    Pandit-Abid, Nami
    Khan, Asif
    Kamat, Siddhesh
    CHEST, 2020, 158 (04) : 1752A - 1754A
  • [34] Cyclosporin A treatment and airways inflammation in corticosteroid-dependent asthma
    Redington, AE
    Hardinge, FM
    Madden, J
    Holgate, ST
    Howarth, PH
    ALLERGY, 1998, 53 (01) : 94 - 98
  • [35] Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan
    Tohda, Yuji
    Matsumoto, Hisako
    Miyata, Masanori
    Taguchi, Yurie
    Ueyama, Maki
    Joulain, Florence
    Arakawa, Ichiro
    JOURNAL OF ASTHMA, 2022, 59 (11) : 2162 - 2173
  • [36] Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma
    Nair, Parameswaran
    Bardin, Philip
    Humbert, Marc
    Murphy, Kevin R.
    Hickey, Lisa
    Garin, Margaret
    Vanlandingham, Rebecca
    Chanez, Pascal
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (02): : 555 - 564
  • [37] A risk benefit assessment of methotrexate in corticosteroid-dependent asthma
    Shulimzon, TR
    Shiner, RJ
    DRUG SAFETY, 1996, 15 (04) : 283 - 290
  • [38] BECLOMETHASONE DIPROPRIONATE AEROSOL IN TREATMENT OF CORTICOSTEROID-DEPENDENT ASTHMA
    SCHOENWETTER, WF
    MINNESOTA MEDICINE, 1977, 60 (05) : 315 - 318
  • [39] Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma
    Brusselle, Guy
    Quirce, Santiago
    Papi, Alberto
    Kuna, Piotr
    Chipps, Bradley E.
    Hanania, Nicola A.
    Blaiss, Michael
    Msihid, Jerome
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    Gall, Rebecca
    Ortiz, Benjamin
    Djandji, Michel
    Radwan, Amr
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (03): : 873 - 884.e11
  • [40] Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients
    Domingo, Christian
    Moreno, Amalia
    Jose Amengual, Ma
    Monton, Concepcion
    Suarez, David
    Pomares, Xavier
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (01) : 45 - 53